A detailed history of Benjamin Edwards Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Benjamin Edwards Inc holds 3,137 shares of REGN stock, worth $2.42 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
3,137
Previous 25 12448.0%
Holding current value
$2.42 Million
Previous $26,000 12580.77%
% of portfolio
0.05%
Previous 0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $3.19 Million - $3.74 Million
3,112 Added 12448.0%
3,137 $3.3 Million
Q2 2024

Aug 12, 2024

BUY
$883.2 - $1071.19 $3,532 - $4,284
4 Added 19.05%
25 $26,000
Q1 2024

Apr 29, 2024

BUY
$902.69 - $993.35 $18,956 - $20,860
21 New
21 $20,000
Q4 2022

Feb 07, 2023

SELL
$705.89 - $766.39 $23,294 - $25,290
-33 Reduced 86.84%
5 $4,000
Q1 2022

May 04, 2022

SELL
$595.12 - $698.43 $8,926 - $10,476
-15 Reduced 28.3%
38 $27,000
Q4 2021

Feb 07, 2022

BUY
$543.48 - $670.97 $28,804 - $35,561
53 New
53 $33,000
Q2 2021

Aug 11, 2021

SELL
$472.8 - $558.54 $14,656 - $17,314
-31 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$446.73 - $548.2 $13,848 - $16,994
31 New
31 $15,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $82.9B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Benjamin Edwards Inc Portfolio

Follow Benjamin Edwards Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

News

Stay updated on Benjamin Edwards Inc with notifications on news.